FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy

Phase 2

Terminated

Conditions: Major Liver Resection

Interventions: Drug: Octreotide
Other: Placebo

First Posted Date: 2017-06-07

Last Posted Date: 2024-02-14

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 23

Registration Number: NCT03179995

Locations: 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Phase 2

Active, not recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: Atezolizumab
Drug: Guadecitabine

First Posted Date: 2017-06-07

Last Posted Date: 2021-11-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 21

Registration Number: NCT03179943

Locations: 🇺🇸
USC Norris Hospital and Clinics, Los Angeles, California, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Impact of Ribociclib on Head and Neck Squamous Cell Cancer

Early Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Ribociclib

First Posted Date: 2017-06-07

Last Posted Date: 2019-02-25

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 1

Registration Number: NCT03179956

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

SMART Project in Preventing Skin Cancer

Not Applicable

Completed

Conditions: Skin Carcinoma

Interventions: Other: Questionnaire Administration
Behavioral: Compliance Monitoring
Other: Health Telemonitoring

First Posted Date: 2017-06-06

Last Posted Date: 2018-08-01

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 114

Registration Number: NCT03177057

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

Phase 1

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: Nivolumab
Drug: Axitinib

First Posted Date: 2017-06-01

Last Posted Date: 2024-10-26

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 98

Registration Number: NCT03172754

Locations: 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
US Oncology and Hematology, Albany, New York, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 1 locations

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Phase 2

Active, not recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Atezolizumab
Drug: Paclitaxel
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2017-04-24

Last Posted Date: 2024-01-03

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 16

Registration Number: NCT03125928

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Phase 2

Active, not recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Ribociclib
Drug: Everolimus

First Posted Date: 2017-04-14

Last Posted Date: 2024-07-12

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 48

Registration Number: NCT03114527

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Decitabine
Drug: Digoxin

First Posted Date: 2017-04-13

Last Posted Date: 2021-03-16

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 1

Registration Number: NCT03113071

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Jeans Hospital, Philadelphia, Pennsylvania, United States

Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: Regorafenib
Drug: 5-FU
Drug: Leucovorin

First Posted Date: 2017-04-04

Last Posted Date: 2022-02-07

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 2

Registration Number: NCT03099486

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

Phase 2

Terminated

Conditions: Endometrial Cancer

Interventions: Drug: ONC201

First Posted Date: 2017-04-04

Last Posted Date: 2024-01-16

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 19

Registration Number: NCT03099499

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy